Clinical Trial Update: International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab [Phase 2]

View source ↗

Summary

An international Phase 2 treatment-extension study of adults with multiple myeloma who have benefited from isatuximab is ongoing (ACTIVE_NOT_RECRUITING).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Isatuximab (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING